Upper Macungie OKs Eli Lilly final land development plan

Eli Lilly's tirzepatide, sold as Mounjaro and Zepbound, became the world's best-selling drug, contributing 65% of Q2 revenue. Clinical trials showed tirzepatide combined with Taltz improved psoriasis and psoriatic arthritis symptoms, expanding potential uses beyond diabetes and obesity. Eli Lilly is testing tirzepatide in other conditions, aiming to secure broader insurance coverage and mitigate competition risks.

In August 2026, the FDA approved Oveporexton (Takeda) for narcolepsy, a first-in-class drug restoring orexin signaling. It also cleared Roche's Elecsys Phospho-Tau test (with Eli Lilly) for Alzheimer's assessment and C2N Diagnostics' PrecivityAD2 for younger adults. REGENXBIO's Hunter syndrome therapy was put on hold, while Cellenkos' ALS therapy received Fast Track designation. Lantheus' Tauklarify, a tau-targeted imaging agent, was approved for AD evaluation.

Eli Lilly's Mounjaro Q2 revenue surged 91% to $9.94 billion, with full-year guidance raised to $85B-$87B. The FDA expanded Mounjaro's label to include cardiovascular benefits, which may help defend diabetes reimbursement as employer coverage for GLP-1 drugs drops. Shares trade at $1,174.61, down 6.44% in the past week.

Eli Lilly's GLP-1 weight-loss pill, Foundayo, is now available in UK pharmacies via private prescription, following MHRA approval. The tablet offers convenience over injectables and has shown significant weight loss in trials. Eli Lilly is working with NICE for potential NHS inclusion. Counterfeit risks are a concern, with 97% of pharmacies worried about unlicensed products. The company is exploring tech solutions for supply chain security.

Eli Lilly (LLY) announced a $2.9B acquisition of Merida Biosciences, adding treatments for autoimmune and allergic diseases to its pipeline. Merida's lead therapy, MER511, is in Phase 1 for Graves' disease. Lilly's strong revenue from GLP-1 drugs, like Mounjaro and Zepbound, fuels its acquisition strategy, with 26 deals since 2023. The global obesity medicine market is projected to grow to $200B by 2027.

Eli Lilly (LLY) reported Q2 2026 revenue of $22.974B, up 48% YoY, with Mounjaro contributing $9.943B. EPS guidance raised to $35.50-$36.50. Shares at $1,156.73, up 8.16% YTD. Analysts see modest upside to $1,315.04, but a model suggests $1,398.96 base case. Potential catalysts include FDA approvals and pipeline developments.